PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection.
From the U.S. FDA-approved label for Erythropoietin. Full label: DailyMed.
PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection. The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
From the U.S. FDA-approved label for Erythropoietin. Full label: DailyMed.
Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment. In pregnant women, lactating women, neonates, infants: Use only single-dose vials.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
PROCRIT is contraindicated in patients with: Uncontrolled hypertension Pure red cell aplasia (PRCA) that begins after treatment with PROCRIT or other erythropoietin protein drugs Serious allergic reactions to PROCRIT PROCRIT from multiple-dose vials contains benzyl alcohol and is contraindicated in: Neonates, infants, pregnant women, and lactating women.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke. Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer. Hypertension: Control hypertension prior to initiating and during treatment with PROCRIT. Seizures: PROCRIT increases the risk for seizures in patients with CKD.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse reactions are discussed in greater detail in other sections of the label: Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer Hypertension Seizures PRCA Serious Allergic Reactions Severe Cutaneous Reactions Patients with CKD: Adverse reactions in ≥ 5% of PROCRIT-treated…
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
7 products from 3 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Epofit 2000 2000IU Tablet | Erythropoietin (2000IU) | Intas Pharmaceuticals Ltd. | |
| Epofit 4000 4000IU Tablet | Erythropoietin (4000IU) | Intas Pharmaceuticals Ltd. | |
| Epofit 6000 6000I.U. Tablet | Erythropoietin (6000I.U.) | Intas Pharmaceuticals Ltd. | |
| Shanpoietin 2000IU Injection | Erythropoietin (2000IU) | Sanofi India Ltd. | |
| Shanpoietin 4000IU Injection | Erythropoietin (4000IU) | Sanofi India Ltd. | |
| Wepox 2000IU Injection | Erythropoietin (2000IU) | Wockhardt Ltd. | |
| Wepox 4000IU Injection | Erythropoietin (4000IU) | Wockhardt Ltd. |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 36°F to 46°F (2°C to 8°C). Do not freeze. Do not shake. Do not use PROCRIT that has been shaken or frozen. Store PROCRIT vials in the original carton until use to protect from light.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
